Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
1.435
+0.045 (3.24%)
Jun 3, 2026, 1:58 PM EDT - Market open
Humacyte Revenue
Humacyte had revenue of $495.00K in the quarter ending March 31, 2026, a decrease of -4.26%. This brings the company's revenue in the last twelve months to $2.02M, up 289.94% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M.
Revenue (ttm)
$2.02M
Revenue Growth
+289.94%
P/S Ratio
158.03
Revenue / Employee
$10,957
Employees
184
Market Cap
318.60M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 63.50M |
| Lineage Cell Therapeutics | 14.78M |
| Abeona Therapeutics | 14.54M |
| Fate Therapeutics | 6.32M |
| Armata Pharmaceuticals | 5.20M |
| Silence Therapeutics | 839.00K |
| InflaRx | 33.82K |
HUMA News
- 2 days ago - Humacyte price target raised to $2 from $1 at Benchmark - TheFly
- 8 days ago - Humacyte announces presentation at VASA meeting on self-repair ATEV - TheFly
- 8 days ago - Humacyte Announces Presentation at VASA Meeting of Research Highlighting Self-Repair of ATEV After Cannulation for Dialysis Access - GlobeNewsWire
- 14 days ago - Humacyte reports Symvess under contract with Strategic Acquisition Center of VA - TheFly
- 14 days ago - Humacyte Announces Symvess® is Now Under Contract with the Strategic Acquisition Center (SAC) of the U.S. Department of Veterans Affairs - GlobeNewsWire
- 20 days ago - Humacyte price target raised to $1.50 from $1 at TD Cowen - TheFly
- 21 days ago - Humacyte reports Q1 EPS (9c), consensus (12c) - TheFly
- 21 days ago - Humacyte Earnings Call Transcript: Q1 2026 - Transcripts